Literature DB >> 16125645

Treatment of severe refractory acute graft-versus-host disease of the gastrointestinal tract with Campath-1H.

Alessandro Busca, Franco Locatelli, Elisabetta Lovisone, Antonio Ottobrelli, Daniela Boggio, Domenico Novero, Michele Falda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16125645     DOI： 10.1016/j.bbmt.2005.05.010

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  4 in total

1.  The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients.

Authors:  Pooja Khandelwal; Julia Lawrence; Alexandra H Filipovich; Stella M Davies; Jacob J Bleesing; Michael B Jordan; Parinda Mehta; Sonata Jodele; Michael S Grimley; Ashish Kumar; Kasiani Myers; Rebecca A Marsh
Journal:  Pediatr Transplant       Date:  2013-10-30

Review 2.  Current and future approaches for control of graft-versus-host disease.

Authors:  John Koreth; Joseph H Antin
Journal:  Expert Rev Hematol       Date:  2008-10       Impact factor: 2.929

3.  A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Pooja Khandelwal; Chie Emoto; Tsuyoshi Fukuda; Alexander A Vinks; Lisa Neumeier; Christopher E Dandoy; Javier El-Bietar; Sharat Chandra; Stella M Davies; Jacob J Bleesing; Michael B Jordan; Parinda A Mehta; Sonata Jodele; Michael S Grimley; Ashish Kumar; Kasiani C Myers; Rebecca A Marsh
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-21       Impact factor: 5.742

4.  Successful treatment of cancer-associated retinopathy with alemtuzumab.

Authors:  Ladan Espandar; Susan O'Brien; Charles Thirkill; Linda A Lubecki; Bita Esmaeli
Journal:  J Neurooncol       Date:  2007-01-25       Impact factor: 4.506
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.